
This is an AstraZeneca promotional activity.
Presentation Objectives:
- Highlight the importance of the estrogen receptor as a critical driver of hormone receptor-positive (HR+) advanced or metastatic breast cancer
- Evaluate the clinical evidence that supports the use of FASLODEX® (fulvestrant) injection for the:
- Treatment of HR+, HER2- advanced breast cancer (ABC) in postmenopausal women not previously treated with endocrine therapy
- Treatment of HR+ ABC in postmenopausal women with disease progression following endocrine therapy
- Treatment of HR+, HER2- advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy
- To review best practices and potential injection-related adverse reactions associated with large-volume IM injections
Please see Important Safety Information for FASLODEX below.
Note: No continuing education (CE) credit will be awarded.
This program is intended for US healthcare professionals only.
AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event.
AstraZeneca fully supports and abides by the PhRMA Code on Interactions With Health Care Professionals (HCPs). This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guest of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a Federal, State, or institution employee, you may be subject to laws, regulations, or rules that prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions. AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits. This is an AstraZeneca promotional activity.
Monday, January 14th

Port Richey, FL
6:30 PM Registration
7:00 PM Start
Catches Waterfront Grille
7811 Bayview St.
Port Richey, FL 34668
Alla Gopenko
Manager Medical Liaison
AstraZeneca Pharmaceuticals LP
Thursday, January 17th

Gainesville. Fl
6:30 PM Registration
7:00 PM Start
Mark’s US Prime
201 Southeast 2nd Avenue Suite 102
Gainesville, FL 32601
Chris Tibbetts, PharmD, BCOP
Senior Medical Science Liaison, Oncology
AstraZeneca Pharmaceuticals LP
Wednesday, January 23rd

Tampa, FL
6:30 PM Registration
7:00 PM Start
Eddie V’s Prime Seafood
4400 West Boy Scout Boulevard
Tampa, FL 33607
Chris Tibbetts, PharmD, BCOP
Senior Medical Science Liaison, Oncology
AstraZeneca Pharmaceuticals LP
Monday, February 4th

New Hyde Park, NY
6:30 PM Registration
7:00 PM Start
Luigi’s Restaurant & Bar
265-21 Union Turnpike
New Hyde Park, NY 11040
Jigna Bhalla
Senior Medical Science Liaison, Oncology
AstraZeneca Pharmaceuticals LP
Indications for FASLODEX
Monotherapy
FASLODEX is an estrogen receptor antagonist indicated for the:
- Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy
- Treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy
Combination Therapy
- FASLODEX in combination with palbociclib or abemaciclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women with disease progression after endocrine therapy
Important Safety Information About FASLODEX
Contraindications
- FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with FASLODEX
Risk of Bleeding
- Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use
Hepatic Impairment
- FASLODEX is metabolized primarily in the liver. A 250 mg dose is recommended in patients with moderate hepatic impairment (Child-Pugh class B). FASLODEX has not been evaluated in patients with severe hepatic impairment (Child-Pugh class C)
Injection Site Reaction
- Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve. Injection site–related events, including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy, have been reported with FASLODEX injection
Embryo-Fetal Toxicity and Lactation
- Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the final dose. Advise lactating women not to breastfeed during treatment with FASLODEX and for 1 year after the final dose because of the potential risk to the infant
Immunoassay Measurement of Serum Estradiol
- Due to structural similarity of fulvestrant and estradiol, FASLODEX can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels
Adverse Reactions
Monotherapy
- The most common adverse reactions occurring in ≥5% of patients receiving FASLODEX 500 mg were injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, myalgia, vomiting, anorexia, diarrhea, asthenia, musculoskeletal pain, cough, dyspnea, and constipation
- Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of FASLODEX patients and were not dose-dependent
Combination Therapy—FASLODEX plus palbociclib
- The most frequently reported Grade ≥3 adverse reactions in patients receiving FASLODEX plus palbociclib in descending frequency were neutropenia and leukopenia
- Adverse reactions (≥10%) of any grade reported in patients receiving FASLODEX 500 mg plus palbociclib 125 mg/day by descending frequency were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, diarrhea, thrombocytopenia, vomiting, alopecia, rash, decreased appetite, and pyrexia
- Additional adverse reactions occurring at an overall incidence of <10% of patients receiving FASLODEX plus palbociclib included asthenia, aspartate aminotransferase increased, dysgeusia, epistaxis, lacrimation increased, dry skin, alanine aminotransferase increased, vision blurred, dry eye, and febrile neutropenia
Combination Therapy—FASLODEX plus abemaciclib
- The most frequently reported (≥5%) Grade 3 or 4 adverse reactions in patients receiving FASLODEX plus abemaciclib were neutropenia, diarrhea, leukopenia, anemia, and infections
- The most common adverse reactions (≥20%) of any grade reported in patients receiving FASLODEX 500 mg plus abemaciclib 150 mg twice daily were diarrhea, fatigue, neutropenia, nausea, infections, abdominal pain, anemia, leukopenia, decreased appetite, vomiting, and headache
Please see accompanying full Prescribing Information with Patient Information for FASLODEX.
FASLODEX is a registered trademark of the AstraZeneca group of companies.
©2018 AstraZeneca. All rights reserved.
US-24394 Last Updated 10/18